Syneron Medical Ltd

Find Ratings Reports
ELOS : NASDAQ : Health Care
$7.02 up 0.13 | 1.89%
Today's Range: 6.89 - 7.05
Avg. Daily Volume: 133,600
09/28/16 - 4:00 PM ET

Financial Analysis


SYNERON MEDICAL LTD's gross profit margin for the second quarter of its fiscal year 2016 is essentially unchanged when compared to the same period a year ago. The company has grown sales and net income during the past quarter when compared with the same quarter a year ago, however, it was unable to keep up with the growth of the average competitor within its industry. SYNERON MEDICAL LTD has strong liquidity. Currently, the Quick Ratio is 1.86 which shows the ability to cover short-term cash needs. The company's liquidity has decreased from the same period last year.

During the same period, stockholders' equity ("net worth") has decreased by 7.63% from the same quarter last year. The key liquidity measurements indicate that the company is unlikely to face financial difficulties in the near future.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.



Income Statement Q2 FY16 Q2 FY15
Net Sales ($mil)74.9773.51
EBITDA ($mil)4.372.16
EBIT ($mil)2.37-0.07
Net Income ($mil)0.98-0.3


Balance Sheet Q2 FY16 Q2 FY15
Cash & Equiv. ($mil)68.3579.25
Total Assets ($mil)279.33304.53
Total Debt ($mil)0.00.0
Equity ($mil)207.38224.52


Profitability Q2 FY16 Q2 FY15
Gross Profit Margin54.2255.51
EBITDA Margin5.822.93
Operating Margin3.16-0.09
Sales Turnover1.020.89
Return on Assets-1.45-1.79
Return on Equity-1.95-2.43
Debt Q2 FY16 Q2 FY15
Current Ratio2.842.9
Debt/Capital0.00.0
Interest Expense0.00.0
Interest Coverage0.00.0


Share Data Q2 FY16 Q2 FY15
Shares outstanding (mil)35.2836.75
Div / share0.00.0
EPS0.03-0.01
Book value / share5.886.11
Institutional Own % n/a n/a
Avg Daily Volume136899.080935.0

Valuation


HOLD. This stock’s P/E ratio is negative, making its value useless in the assessment of premium or discount valuation, only displaying that the company has negative earnings per share. For additional comparison, its price-to-book ratio of 1.21 indicates a significant discount versus the S&P 500 average of 2.82 and a significant discount versus the industry average of 5.05. The price-to-sales ratio is well below both the S&P 500 average and the industry average, indicating a discount. After reviewing these and other key valuation criteria, SYNERON MEDICAL LTD proves to trade at a discount to investment alternatives within the industry.


Price/Earnings
1 2 3 4 5
premium   discount
  Price/Cash Flow
1 2 3 4 5
premium   discount
ELOS NM Peers 44.20   ELOS 46.47 Peers 28.91

Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.

ELOS's P/E is negative making this valuation measure meaningless.

 

Premium. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.

ELOS is trading at a significant premium to its peers.

 
Price/Projected
Earnings
1 2 3 4 5
premium   discount
  Price to
Earnings/Growth
1 2 3 4 5
premium   discount
ELOS 15.80 Peers 25.07   ELOS NA Peers 0.84

Average. An average price-to-projected earnings ratio can signify an industry neutral stock price and average future growth expectations.

ELOS is trading at a valuation on par with its peers.

 

Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.

Ratio not available.

 
Price/Book
1 2 3 4 5
premium   discount
  Earnings Growth
1 2 3 4 5
lower   higher
ELOS 1.21 Peers 5.05   ELOS 26.67 Peers 23.13

Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.

ELOS is trading at a significant discount to its peers.

 

Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.

ELOS is expected to have an earnings growth rate that exceeds its peers.

 
Price/Sales
1 2 3 4 5
premium   discount
  Sales Growth
1 2 3 4 5
premium   discount
ELOS 0.88 Peers 14.71   ELOS 4.94 Peers 18.35

Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.

ELOS is trading at a significant discount to its industry on this measurement.

 

Lower. A sales growth rate that trails the industry implies that a company is losing market share.

ELOS significantly trails its peers on the basis of sales growth

 

 

Latest Stock Upgrades/Downgrades